Particularly useful in patients with refractory ITP where other forms of therapy have been ineffective. Its unique mechanism of action differs from other drugs used in ITP, making it an alternative for patients who do not respond to corticosteroids-, IVIG-, or TPO-RA-based therapies. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.